Multi-Center, Randomized, Open-Label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea.
Phase of Trial: Phase III
Latest Information Update: 07 Oct 2016
At a glance
- Drugs T-lymphocyte cell therapy (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- 07 Oct 2016 According to media release treatment group achieved extension of PFS by 1.5 times and 30% higher disease control rate (DCR) than control group.
- 05 Oct 2016 Results published in the Media Release
- 05 Oct 2016 According to media release, data from this study was published in Oncotarget, a prominent international journal.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History